Healthy Skepticism Library item: 6875

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Nathan DG, Weatherall DJ.
Academia and industry: lessons from the unfortunate events in Toronto.
Lancet 1999 Mar 6; 353:(9155):771-2
http://linkinghub.elsevier.com/retrieve/pii/S0140673699000720

Abstract:

The key question in the controversy about deferiprone, Dr. Nancy Olivieri and the drug company Apotex is whether during the course of a drug trial under the auspices of a pharmaceutical company, clinical scientists have the duty to disclose any concerns that they may have about a particular drug to their patients and to the scientific community during the course of the study. There are lessons for the entire biomedical community fromthis unfortunate episode.

Keywords:
*analysis//Canada/deferiprone/Apotex/Hospital for Sick Children/ drug company sponsored research/ bioethics/ guidelines, discussion of/ Research Ethics Boards/ relationship between researchers, academic institutions and industry/ETHICAL ISSUES IN PROMOTION: ETHICS OF TRIALS/SPONSORSHIP: RESEARCH Academic Medical Centers*/legislation & jurisprudence Academic Medical Centers*/trends Clinical Trials/legislation & jurisprudence Drug Industry*/legislation & jurisprudence Drug Industry*/trends Humans Iron Chelating Agents/therapeutic use Ontario Pyridones/therapeutic use Thalassemia/drug therapy